Catalogue

Background
Lysophospholipid acyltransferases (LPLATs) catalyse the addition of fatty acyl moieties to the glycerol backbone of lysophospholipids . In addition to playing a crutial role in the synthesis of structural membrane components the LPLATs are also implicated in cellular signalling responses for cytokines, growth factors and other agonists. Cellular signalling through the interleukin 1 receptor in human mesangial cells and EL-4 cells proceeds by the activation of lysophosphatidic acid acyltransferase (LPAAT). Activation of LPAAT by interleukin 1 results in the generation of unsaturated phosphatidic acid species, that are crucial to the generation of diacylglycerol and interleukin 1 signalling. LPLATs are also involved in signalling for increased interleukin 2 synthesis through the T cell antigen receptor. Activation of T-cells via anti-CD3 stimulation has been shown to increase incorporation of polyunsaturated fatty acids into phosphatidylcholine via lysophosphatidylcholine acyltransferase. Activation of this enzyme is essential for the sustained activation and translocation of protein kinase C.

Synonyms: 1-AGP acyltransferase 2, 1-AGPAT 2,1-acylglycerol-3-phosphate O-acyltransferase 2, LPAAT-β, 2

Source

Immunogen: Synthetic peptide derived from the LPAAT- protein

Product

Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffiinity Purification

Concentration: See vial for concentration

Applications
Antibody can be used for Western blotting (5-10 µg/ml) and EIA. Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Positive Control: Human brain lysate (Cat. No. X1633C)

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
[1] Eberhardt C., Gray P.W., Tjoelker L.W.; Human lysophosphatidic acid acyltransferase. cDNA cloning, expression, and localization to chromosome 9q34.3.; J. Biol. Chem. 272:20299-20305(1997). [2] Stamps A.C., Elmore M.A., Hill M.E., Kelly K., Makda A.A., Finnen M.J.; A human cDNA sequence with homology to non-mammalian lysophosphatidic acid acyltransferases.; Biochem. J. 326:455-461(1997). [3] West J., Tompkins C.K., Balantac N., Nudelman E., Meengs B., White T., Bursten S., Coleman J., Kumar A., Singer J.W., Leung D.W.; Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells.; DNA Cell Biol. 16:691-701(1997). [4] Leung D.W., Tompkin C.K., West J.; Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases. [5] Strausberg R.L., et al Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.; Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002). [6] Garg A.; Acquired and inherited lipodystrophies.; N. Engl. J. Med. 350:1220-1234(2004). [7] Agarwal A.K., Arioglu E., de Almeida S., Akkoc N., Taylor S.I., Bowcock A.M., Barnes R.I., Garg A.; AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34.; Nat. Genet. 31:21-23(2002).

Protein Reference(s)

Database Name: UniProt

Accession Number: O15120

Species Accession: Human

Safety Datasheet(s) for this product: